Target
TET2
10 abstracts
Abstract
Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.Org: Gustave Roussy Cancer Campus, Gustave Roussy Département d'Organisation du Parcours Patient, Paris Saclay University, Department of Biostatistics and Epidemiology, Department of Medical Biology and Pathology, Gustave Roussy, France, Paris,
Abstract
Clonal hematopoiesis in survivors of childhood cancer.Org: New York City, St Louis, Washington University School of Medicine, ModernaTX, St. Louis,
Abstract
Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Hematopathology, Beijing Friendship Hospital, Capital Medical University,
Abstract
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).Org: Novartis Pharma AG, Novartis Oncology, Genesis Research, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yale School of Medicine,
Abstract
Methylation-based prediction of myelodysplastic syndrome survival outcomes.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Columbia University - Mailman School of Public Health, Columbia University Medical Center,
Abstract
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,
Abstract
Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.Org: Data Driven Bioscience, Indiana University – Purdue University Indianapolis, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University Department of General Internal Medicine, Indiana University Hospital,